Farkouh ME, Greenberg BP: An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009, 103 (9): 1227-1237. 10.1016/j.amjcard.2009.01.014.
Article
CAS
PubMed
Google Scholar
Strand V: Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. Lancet. 2007, 370 (9605): 2138-2151. 10.1016/S0140-6736(07)61909-6.
Article
CAS
PubMed
Google Scholar
Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006, 332 (7553): 1302-1308. 10.1136/bmj.332.7553.1302.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hennekens CH, Borzak S: Cyclooxygenase-2 inhibitors and most traditional nonsteroidal anti-inflammatory drugs cause similar moderately increased risks of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2008, 13 (1): 41-50. 10.1177/1074248407312990.
Article
CAS
PubMed
Google Scholar
Chen YF JP, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS: Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess. 2008, 12 (11): 1-278.
CAS
PubMed
Google Scholar
Friedewald VE, Bennett JS, Packer M, Roberts WC, Williams GW: The Editor's Roundtable: Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk. The American Journal of Cardiology. 2008, 102 (8): 1046-1055. 10.1016/j.amjcard.2008.08.004.
Article
PubMed
Google Scholar
Hermann M: Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep. 2009, 11 (1): 31-35. 10.1007/s11926-009-0005-5.
Article
CAS
PubMed
Google Scholar
Vardeny O, Solomon SD: Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk. Cardiol Clin. 2008, 26 (4): 589-601. 10.1016/j.ccl.2008.06.004.
Article
PubMed
Google Scholar
Cheng JW: Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events. Ann Pharmacother. 2006, 40 (10): 1785-1796. 10.1345/aph.1H048.
Article
CAS
PubMed
Google Scholar
White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM: Risk of Cardiovascular Events in Patients Receiving Celecoxib: A Meta-Analysis of Randomized Clinical Trials. The American Journal of Cardiology. 2007, 99 (1): 91-98. 10.1016/j.amjcard.2006.07.069.
Article
CAS
PubMed
Google Scholar
McGettigan P, Henry D: Cardiovascular Risk and Inhibition of Cyclooxygenase: A Systematic Review of the Observational Studies of Selective and Nonselective Inhibitors of Cyclooxygenase 2. JAMA. 2006, 296 (13): 1633-1644. 10.1001/jama.296.13.jrv60011.
Article
CAS
PubMed
Google Scholar
Salpeter SR, Gregor P, Ormiston TM, Whitlock R, Raina P, Thabane L, Topol EJ: Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am J Med. 2006, 119 (7): 552-559. 10.1016/j.amjmed.2005.10.056.
Article
CAS
PubMed
Google Scholar
National Health Insurance in Taiwan 2010. [http://www.nhi.gov.tw/resource/Webdata/Attach_15634_1_National Health Insurance in Taiwan 2010.pdf]
Waksman JC, Brody A, Phillips SD: Nonselective Nonsteroidal Antiinflammatory Drugs and Cardiovascular Risk: Are They Safe?. Ann Pharmacother. 2007, 41 (7): 1163-1173. 10.1345/aph.1H341.
Article
CAS
PubMed
Google Scholar
Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL: Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007, 66 (10): 1296-1304. 10.1136/ard.2006.068650.
Article
CAS
PubMed
PubMed Central
Google Scholar
Joshi GP, Gertler R, Fricker R: Cardiovascular Thromboembolic Adverse Effects Associated with Cyclooxygenase-2 Selective Inhibitors and Nonselective Antiinflammatory Drugs. Anesthesia & Analgesia. 2007, 105 (6): 1793-1804. 10.1213/01.ane.0000286229.05723.50.
Article
CAS
Google Scholar
Gislason GH, Rasmussen JN, Abildstrom SZ, Schramm TK, Hansen ML, Fosbol EL, Sorensen R, Folke F, Buch P, Gadsboll N, Rasmussen S, Poulsen HE, Kober L, Madsen M, Torp-Pedersen C: Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med. 2009, 169 (2): 141-149. 10.1001/archinternmed.2008.525.
Article
CAS
PubMed
Google Scholar
Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Kober L, Madsen M, Torp-Pedersen C: Risk of Death or Reinfarction Associated With the Use of Selective Cyclooxygenase-2 Inhibitors and Nonselective Nonsteroidal Antiinflammatory Drugs After Acute Myocardial Infarction. Circulation. 2006, 113 (25): 2906-2913. 10.1161/CIRCULATIONAHA.106.616219.
Article
CAS
PubMed
Google Scholar
Roumie CL, Choma NN, Kaltenbach L, Mitchel EF, Arbogast PG, Griffin MR: Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease. Pharmacoepidemiology and Drug Safety. 2009, 18 (11): 1053-1063. 10.1002/pds.1820.
Article
CAS
PubMed
Google Scholar
van Staa TP, Rietbrock S, Setakis E, Leufkens HG, Leufkens HGM: Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?. Journal of Internal Medicine. 2008, 264 (5): 481-492. 10.1111/j.1365-2796.2008.01991.x.
Article
PubMed
Google Scholar
Hammad TA, Graham DJ, Staffa JA, Kornegay CJ, Pan GJD: Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiology and Drug Safety. 2008, 17 (4): 315-321. 10.1002/pds.1560.
Article
PubMed
Google Scholar
Solomon DH, Avorn J, Sturmer T, Glynn RJ, Mogun H, Schneeweiss S: Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: High-risk subgroups and time course of risk. Arthritis & Rheumatism. 2006, 54 (5): 1378-1389. 10.1002/art.21887.
Article
CAS
Google Scholar
Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS, Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, Rimm EB, Willett WC, Fuchs CS: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006, 113 (12): 1578-1587. 10.1161/CIRCULATIONAHA.105.595793.
Article
CAS
PubMed
Google Scholar
Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A, Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of Internal Medicine. 2003, 163 (4): 481-486. 10.1001/archinte.163.4.481.
Article
CAS
PubMed
Google Scholar
Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR, Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR: Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet. 2002, 359 (9301): 118-123. 10.1016/S0140-6736(02)07370-1.
Article
CAS
PubMed
Google Scholar
Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet. 2002, 360 (9339): 1071-10.1016/S0140-6736(02)11131-7.
Article
CAS
PubMed
Google Scholar
Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL: The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. Journal of the American College of Cardiology. 2004, 43 (6): 985-990. 10.1016/j.jacc.2003.08.064.
Article
CAS
PubMed
Google Scholar
Fischer LM, Schlienger RG, Matter CM, Jick H, Meier CR: Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction. Pharmacotherapy. 2005, 25 (4): 503-510. 10.1592/phco.25.4.503.61021.
Article
CAS
PubMed
Google Scholar
Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction.[Summary for patients in Ann Intern Med. 2005 Feb 1;142(3):I21; PMID: 15684199]. Annals of Internal Medicine. 2005, 142 (3): 157-164.
Article
CAS
PubMed
Google Scholar
Mangoni AA, Woodman RJ, Gaganis P, Gilbert AL, Knights KM: Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community. British Journal of Clinical Pharmacology. 2010, 69 (6): 689-700. 10.1111/j.1365-2125.2010.03627.x.
Article
PubMed
PubMed Central
Google Scholar
Garcia Rodriguez LA, Tacconelli S, Patrignani P, Garcia Rodriguez LA, Tacconelli S, Patrignani P: Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. Journal of the American College of Cardiology. 2008, 52 (20): 1628-1636. 10.1016/j.jacc.2008.08.041.
Article
PubMed
Google Scholar
Helin-Salmivaara A, Virtanen A, Vesalainen R, Gronroos JM, Klaukka T, Idanpaan-Heikkila JE, Huupponen R: NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case? control study from Finland. European Heart Journal. 2006, 27 (14): 1657-1663. 10.1093/eurheartj/ehl053.
Article
PubMed
Google Scholar
Hawkey CJ, Hawkey GM, Everitt S, Skelly MM, Stack WA, Gray D: Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology. 2006, 61 (6): 730-737. 10.1111/j.1365-2125.2006.02644.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Andersohn F, Suissa S, Garbe E, Andersohn F, Suissa S, Garbe E: Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation. 2006, 113 (16): 1950-1957. 10.1161/CIRCULATIONAHA.105.602425.
Article
CAS
PubMed
Google Scholar
Levesque LE, Brophy JM, Zhang B, Levesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.[Summary for patients in Ann Intern Med. 2005 Apr 5;142(7):I45; PMID: 15809454]. Annals of Internal Medicine. 2005, 142 (7): 481-489.
Article
CAS
PubMed
Google Scholar
Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT: Risk of Hospitalization for Myocardial Infarction Among Users of Rofecoxib, Celecoxib, and Other NSAIDs: A Population-Based Case-Control Study. Arch Intern Med. 2005, 165 (9): 978-984. 10.1001/archinte.165.9.978.
Article
CAS
PubMed
Google Scholar
Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005, 330 (7504): 1366-10.1136/bmj.330.7504.1366.
Article
CAS
PubMed
PubMed Central
Google Scholar
Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. The Lancet. 2005, 365 (9458): 475-481.
Article
CAS
Google Scholar
Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J: Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004, 109 (17): 2068-2073. 10.1161/01.CIR.0000127578.21885.3E.
Article
CAS
PubMed
Google Scholar
Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez-Perez A: Nonsteroidal Antiinflammatory Drugs and the Risk of Myocardial Infarction in the General Population. Circulation. 2004, 109 (24): 3000-3006. 10.1161/01.CIR.0000132491.96623.04.
Article
CAS
PubMed
Google Scholar
Watson DJ, Rhodes T, Cai B, Guess HA: Lower Risk of Thromboembolic Cardiovascular Events With Naproxen Among Patients With Rheumatoid Arthritis. Arch Intern Med. 2002, 162 (10): 1105-1110. 10.1001/archinte.162.10.1105.
Article
CAS
PubMed
Google Scholar
Solomon DH, Glynn RJ, Levin R, Avorn J: Nonsteroidal Anti-inflammatory Drug Use and Acute Myocardial Infarction. Arch Intern Med. 2002, 162 (10): 1099-1104. 10.1001/archinte.162.10.1099.
Article
CAS
PubMed
Google Scholar
Schlienger RG, Jick H, Meier CR: Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol. 2002, 54 (3): 327-332. 10.1046/j.1365-2125.2002.01637.x.
Article
CAS
PubMed
PubMed Central
Google Scholar
Garcia Rodriguez LA, Varas C, Patrono C: Differential Effects of Aspirin and Non-Aspirin Nonsteroidal Antiinflammatory Drugs in the Primary Prevention of Myocardial Infarction in Postmenopausal Women. Epidemiology. 2000, 11 (4): 382-387. 10.1097/00001648-200007000-00004.
Article
CAS
PubMed
Google Scholar
Jick H, Kaye JA, Russmann S, Jick SS, Jick H, Kaye JA, Russmann S, Jick SS: Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors. Pharmacotherapy. 2006, 26 (10): 1379-1387. 10.1592/phco.26.10.1379.
Article
CAS
PubMed
Google Scholar
Brophy JM, Lévesque LE, Zhang B: The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart. 2007, 93 (2): 189-194.
Article
CAS
PubMed
Google Scholar
van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RMC: The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs. Annals of the Rheumatic Diseases. 2009, 68 (5): 668-673. 10.1136/ard.2007.087254.
Article
CAS
PubMed
Google Scholar
Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E, for the Cross Trial Safety Assessment Group: Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis. Circulation. 2008, 117 (16): 2104-2113. 10.1161/CIRCULATIONAHA.108.764530.
Article
CAS
PubMed
PubMed Central
Google Scholar
Delaney JA, Suissa S: The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res. 2009, 18 (1): 53-65. 10.1177/0962280208092346.
Article
PubMed
Google Scholar
Schneeweiss S, Sturmer T, Maclure M: Case-crossover and case-time-control designs as alternatives in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 1997, 6 (Suppl 3): S51-59.
Article
PubMed
Google Scholar
Maclure M: The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events. Am J Epidemiol. 1991, 133 (2): 144-153.
CAS
PubMed
Google Scholar
The Anatomical Therapeutic Chemical (ATC) classification system and the Defined Daily Dose (DDD). [http://www.whocc.no/]
Arora S, Wagner JG, Herbert M: Myth: Parenteral ketorolac provides more effective analgesia than oral ibuprofen. CJEM: The Journal of the Canadian Association of Emergency Physicians. 2007, 9 (1): 30-32.
Google Scholar
Kimmel SE, Berlin JA, Kinman JL, Hennessy S, Feldman H, Carson JL, Strom BL: Parenteral ketorolac and risk of myocardial infarction. Pharmacoepidemiology and Drug Safety. 2002, 11 (2): 113-119. 10.1002/pds.670.
Article
CAS
PubMed
Google Scholar
Reinhart DJ: Minimising the adverse effects of ketorolac. Drug Saf. 2000, 22 (6): 487-497. 10.2165/00002018-200022060-00007.
Article
CAS
PubMed
Google Scholar
Feldman HI, Kimmel SE: Parenteral ketorolac: The risk for acute renal failure. Annals of Internal Medicine. 1997, 126 (3): 193-
Article
CAS
PubMed
Google Scholar
Chang C-H, Shau W-Y, Kuo C-W, Chen S-T, Lai M-S: Increased Risk of Stroke Associated With Nonsteroidal Anti-Inflammatory Drugs: A Nationwide Case-Crossover Study. Stroke. 2010, 41 (9): 1884-1890. 10.1161/STROKEAHA.110.585828.
Article
CAS
PubMed
Google Scholar
Department of Health, regulatory document.
Layton D, Hughes K, Harris S, Shakir SA, Layton D, Hughes K, Harris S, Shakir SAW: Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology. 2003, 42 (11): 1354-1364. 10.1093/rheumatology/keg401.
Article
CAS
PubMed
Google Scholar
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib Study I: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine. 2005, 352 (11): 1071-1080. 10.1056/NEJMoa050405.
Article
CAS
PubMed
Google Scholar
White WB, Faich G, Borer JS, Makuch RW: Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. The American Journal of Cardiology. 2003, 92 (4): 411-418. 10.1016/S0002-9149(03)00659-3.
Article
CAS
PubMed
Google Scholar
Garcia Rodriguez L, Gonzalez-Perez A: Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Medicine. 2005, 3 (1): 17-10.1186/1741-7015-3-17.
Article
PubMed
PubMed Central
Google Scholar
Fosbol EL, Gislason GH, Jacobsen S, Abildstrom SZ, Hansen ML, Schramm TK, Folke F, Sorensen R, Rasmussen JN, Kober L, Madsen M, Torp-Pedersen C: The pattern of use of non-steroidal anti-inflammatory drugs (NSAIDs) from 1997 to 2005: a nationwide study on 4.6 million people. Pharmacoepidemiology & Drug Safety. 2008, 17 (8): 822-833. 10.1002/pds.1592.
Article
Google Scholar
Vlahovic-Palcevski V, Wettermark B, Bergman U, Vlahovic-Palcevski V, Wettermark B, Bergman U: Quality of non-steroidal anti-inflammatory drug prescribing in Croatia (Rijeka) and Sweden (Stockholm). European Journal of Clinical Pharmacology. 2002, 58 (3): 209-214. 10.1007/s00228-002-0449-2.
Article
CAS
PubMed
Google Scholar
Arellano FM, Yood MU, Wentworth CE, Oliveria SA, Rivero E, Verma A, Rothman KJ: Use of cyclo-oxygenase 2 inhibitors (COX-2) and prescription non-steroidal anti-inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX-2 cardiovascular profile. Pharmacoepidemiology and Drug Safety. 2006, 15 (12): 861-872. 10.1002/pds.1343.
Article
CAS
PubMed
Google Scholar
White WB: Defining the problem of treating the patient with hypertension and arthritis pain. American Journal of Medicine. 2009, 122 (5 Suppl): S3-9.
Article
PubMed
Google Scholar
Lee C-H, Wang J-D, Chen P-C: Increased risk of hospitalization for acute hepatitis in patients with previous exposure to NSAIDs. Pharmacoepidemiology and Drug Safety. 2010, 19 (7): 708-714. 10.1002/pds.1966.
Article
CAS
PubMed
Google Scholar